So there are phases of clinical trials and maybe you could talk a little bit about what first phase one clinical trials are like.

Yeah.

So, I mean, I think most people would appreciate that when a new drug is developed by scientists and laboratories, that there's a long process between that point and when it shows up on a pharmacist's shelf.

And it's a series of first studies before it even gets to clinical trials done in laboratories and in animal models to show that the drug is doing what we want in terms of inside cancer cells and that it's safe in animals.

And then It's tested in humans first in a type of trial called a phase one trial, which has several purposes.

One is to figure out what the right dose of the drug is to use in patients.

Another is to make sure that it's safe to use in patients and what are the side effects since all of our drugs have side effects.

So what's it like for a patient to be on a trial as opposed to getting standard treatment?

So, Ian, can you paint a picture for us of how these pathways interact and clinically what we see in terms of the benefit of anti-hurt therapy based on ER?

Yeah, no, I think it's a great question and certainly one that matters to us in the clinic.

I mean, I think the simplest way to, at least the simplest way I think about the fact of what's going on inside of a triple positive cancer is that you now, in those cancers, you have two drivers of proliferation.

You have both ER and HER2.

And When they're both on, they tend to antagonize each other a little bit.

When HER2 is driving a cancer, it tends to suppress ER.

from the clinic in our, from what we think is most important is that when you block just one of those two pathways, the other one can take over the growth of the cancer.

And then, of course, the question that a lot of people ask, which is, would you go to the patina regimen of AI, Palbo, and Trastuzumab? Quote, is this your new standard? Ian, any thoughts about this case?

Ian?

Yeah.

So, you know, we've had, you know, pretty long stability of our first and second line therapies for HER2 positive disease.

You know, we used THP in the first line, TDM1 in the second line.

But then in the last few years, obviously, we've seen big changes in that.

And that's largely because of the development of trastuzumab duroxacin.

which was originally shown in very pretreated patients to have very durable benefit in DBO1.

ER positive patients.